Microscopic image of the calf muscle from a person with Duchenne muscular dystrophy, where muscle fibres have been replaced by fat cells. Credit: Dr. Edwin P. Ewing, Jr.

Sarepta Therapeutics is planning to submit a new drug application (NDA) to the US Food and Drug Administration (FDA) for accelerated approval of its therapeutic candidate golodirsen (srp-4053) to treat patients with duchenne muscular dystrophy (DMD).

The move comes after the biopharmaceutical company received guidance on the development pathway for golodirsen from the FDA’s Division of Neurology Products.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Golodirsen is a phosphordiamidate morpholino oligimer being developed for patients with genetic mutations subject to skipping exon 53 of the DMD gene.

Sarepta Therapeutics president and CEO Doug Ingram said: “Obviously, whether golodirsen will obtain accelerated approval is a review decision that will come after the submission and review of our NDA. But we greatly appreciate the willingness of the neurology division to engage and provide clear direction to us on the steps necessary to support an NDA submission for accelerated approval.”

“We greatly appreciate the willingness of the neurology division to engage and provide clear direction to us on the steps necessary to support an NDA submission for accelerated approval.”

In a Phase I/II clinical trial, statistically significant data was obtained for all biological endpoints following golodirsen treatment in patients with deletions of the DMD gene amenable to exon 53 skipping.

The study was conducted to assess the safety, tolerability, pharmacokinetics and efficacy of golodirsen.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Currently, the efficacy of the drug candidate and casimersen is being investigated in a randomised, double-blind, placebo-controlled Phase III trial (ESSENCE). If the FDA grants accelerated approval, ESSENCE is set to be a post-marketing confirmatory study.

The FDA’s neurology division said that the NDA should include results from long-term animal toxicology studies, which are scheduled to be concluded in the fourth quarter of 2018.